kabutan

Oncolys BioPharma receives 'conformity' notification for OBP-301 document review and GCP inspection

Fri Apr 3, 2026 5:56 pm JST Catalyst

Oncolys BioPharma Inc. <4588> announced after the close of trading on the 3rd that it has received a notification of 'conformity' from the Pharmaceuticals and Medical Devices Agency (PMDA) regarding the conformity document review and GCP on-site inspection for its oncolytic virus OBP-301 targeting esophageal cancer, for which it filed a marketing authorization application in December last year. The company plans to begin sales of OBP-301 from the fiscal year ending December 2026 after obtaining marketing authorization from the Minister of Health, Labour and Welfare.

Source: MINKABU PRESS

Related Articles